Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

Stay Up To Date With Our News & Insights

Stay informed with current news about our portfolio companies, events and industry insights.

You are subscribed to our newsletters

Oops! Something went wrong while submitting the form.

CincyTech is a venture capital firm that invests in innovative founders tackling the world's complex challenges. Our experienced team is fluent in the language of founders, researchers, and inventors working with deep domain expertise and market foresight. We partner early to help transform ideas into world-class companies.

2900 Reading Rd. Ste. 410 Cincinnati, OH 45206

Contact CincyTech

Home Approach Portfolio Team Community News & Insights Pitch Us

Careers University Programs Disclosures

Made by 5Four Digital®

Kurome Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for KME-0584 for the Treatment of Acute Myeloid Leukemia (AML) and High-Risk Myelodysplastic Syndromes (MDS)

Recent News & Insights

Abre Secures $24 Million Series A Investment to Fuel Growth and Student Impact in K-12 Education

Advancing Data in K-12 Education with Abre

ActionStreamer Technology Showcased By FOX Sports and Tech-Driven UFL During Inaugural Season

Stay Up To Date With Our News & Insights